{"name":"Acerus Biopharma Inc.","slug":"acerus-biopharma-inc","ticker":"","exchange":"","domain":"","description":"Acerus Biopharma Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative treatments in men's health. The company's lead product, Natesto, a testosterone nasal gel, was discontinued. Despite this, Acerus continues to explore opportunities to enhance its portfolio and address unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxOcWdtWlF4SU1sUzlOOXlKU2g1Yjh6YlYzS0ZYSlFuZHhubDhYd19Cc0V2NUFEcXlSeURLbkVzSHBSaWFEWFRKVnJKbFpkby1pa3VGR3k3UHlnOF9Gd1NlTk55WmlsQ0FMLTU4ZWNkUmF0azVRVGJYTnlaQ2g4bFFVeVI3djFZWXBNZ1BMT0MwTlVfdUZMeEZ6SW1pak1udWFHUldYLU9pemh2b0YxSGttRnBoZnd6SU9TOVl1cjAwcHRSaDRxSEQzaVBmVnFNdDFQMzhFRVNrOU9ONEdLTHB6ZDE3aGtqNTNRdF8tYXJYNWQ4cnRCVTR2cUtfa0IxVDZWa3FRa0h0UFUxMVJ5bFF0aVYybjNzb29nTWJISVEyU1g3aVhzSjRQNlV1cjJkV2FKRmd3TVVmR24wWjRrWUxOLXh6X1NqUmVMUUNIZFFxdEJTZ1ZoZmN6TFRVaWN3U0huc2tNdQ?oc=5","date":"2024-03-13","type":"deal","source":"Business Wire","summary":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com - Busin","headline":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNbjJwR2pkc0hpbXVCWU5WOENVd1JpUk1YSVE3TDRyNkg2S0sxTkVLQTlHZDkwYjVyZnRhWVc2Sm52YURXZHd5Z210ak1ZTjRJdmpNV2JfUjlydjlyWkFmejVXRE5kdXRabHRUendpN19nVi1DZXZ1MGtrWlk4eFdzX0ZwMGhxLXNJYmJuTEZIdjFnSnNKQ0o3RWI0RWx1eFVBM3ZCb09uTmo0ajI4bFhxNU5PdkZCck5qOWYyTS02UDR3UGVNc2VFZ1g5MnlETGY0LUd4V0pTeVdFSXdUNE5URDdqckJabmZRSVFYT3YtSUdIZw?oc=5","date":"2023-03-14","type":"regulatory","source":"globenewswire.com","summary":"Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process - globenewswire.com","headline":"Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQZVNqWkljUVNQTTZPSGNnSDdzbHRLNFBlS0dWdVJrWmpCcTR1NUJHMVE1VU1rcGRyOHc2YmQ1LXk1MTFMcjV4VG1WNGdGQURBenJXRVBhSkQ1TUZMbGUzcHRDX1prdXBqVnRSNmgwcFUwQ3QwT1UzREhkMURfZ2ZsbkRiWFBMRUNHeG9UNzhCSENyaDFtbGF5bNIBVkFVX3lxTFBuXzJWSE5qSXVsME5pakJSeXNPLW5nTDFDWndPV21Vb0JtSmdvckxlR3BKYXQwdjdpXzMyRjRYd3U1ajdRMHN4OXh3azJFaGY5UUZLNDdB?oc=5","date":"2023-01-30","type":"pipeline","source":"Law360","summary":"Canadian Pharma Co.'s Units File $61M Ch. 15 In Delaware - Law360","headline":"Canadian Pharma Co.'s Units File $61M Ch. 15 In Delaware - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNQnc5cEZqT0tUWHNqUVhhMVVXb0tjdnJra2laSDVqVVJabXlfdXk3QVkzZXNKSTR1aDVkVktSR05kNFdYRm9WMF84bGEyakFweGlVRi1LMGtURjNLTGdaYUdGbEU1a2tQV1hBWmJTRnBCNW1RUmNKMk5LdjdHYVloZ2N4VC1yejJCeklRaUtaSzVoV2gzMnY5bk0ycFJDcE16X0xuNTZ4UnRjemc?oc=5","date":"2022-09-21","type":"pipeline","source":"Fierce Biotech","summary":"Cash-depleted Acerus undergoes strategic review to stay afloat - Fierce Biotech","headline":"Cash-depleted Acerus undergoes strategic review to stay afloat","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-01-28","type":"pipeline","source":"Cantech Letter","summary":"Acerus Pharmaceutical gets a target price reduction from Mackie Research - Cantech Letter","headline":"Acerus Pharmaceutical gets a target price reduction from Mackie Research","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}